294 related articles for article (PubMed ID: 15685669)
21. A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry.
Owen A; Spinks J; Meehan A; Robb T; Hardy M; Kwasha D; Wlodarczyk J; Reid C
J Med Econ; 2008; 11(2):235-43. PubMed ID: 19450082
[TBL] [Abstract][Full Text] [Related]
22. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
[No Abstract] [Full Text] [Related]
23. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.
Neumann PJ; Chambers JD; Simon F; Meckley LM
Health Aff (Millwood); 2011 Dec; 30(12):2329-37. PubMed ID: 22147861
[TBL] [Abstract][Full Text] [Related]
24. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
25. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
[TBL] [Abstract][Full Text] [Related]
26. A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries.
Barnieh L; Manns B; Harris A; Blom M; Donaldson C; Klarenbach S; Husereau D; Lorenzetti D; Clement F
Value Health; 2014; 17(1):98-108. PubMed ID: 24438723
[TBL] [Abstract][Full Text] [Related]
27. [Pharmacoeconomics--survey and status].
Pedersen KM
Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
[TBL] [Abstract][Full Text] [Related]
28. Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts.
Kannarkat JT; Good CB; Kelly E; Parekh N
J Manag Care Spec Pharm; 2020 Jan; 26(1):63-66. PubMed ID: 31880231
[TBL] [Abstract][Full Text] [Related]
29. Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach.
Antonanzas F; Juarez-Castello C; Rodriguez-Ibeas R
Health Econ Policy Law; 2011 Jul; 6(3):391-403. PubMed ID: 21338542
[TBL] [Abstract][Full Text] [Related]
30. Industry warily eyes new Medicare drug plan.
Vastag B
Nat Biotechnol; 2006 Feb; 24(2):120. PubMed ID: 16465141
[No Abstract] [Full Text] [Related]
31. Incentives in the Medicare prescription drug benefit.
Natl Bur Econ Res Bull Aging Health; 2006; (15):1-2. PubMed ID: 16805056
[No Abstract] [Full Text] [Related]
32. When success sours: PBMs under scrutiny.
Carroll J
Manag Care; 2002 Sep; 11(9):20-6. PubMed ID: 12369344
[No Abstract] [Full Text] [Related]
33. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
34. In search of a corrected prescription drug elasticity estimate: a meta-regression approach.
Gemmill MC; Costa-Font J; McGuire A
Health Econ; 2007 Jun; 16(6):627-43. PubMed ID: 17238227
[TBL] [Abstract][Full Text] [Related]
35. When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing.
Balderrama F; Schwartz LJ; Longo CJ
Health Care Anal; 2020 Jun; 28(2):121-136. PubMed ID: 32232611
[TBL] [Abstract][Full Text] [Related]
36. Economic evaluation for pharmaceuticals in Germany.
Jönsson B
Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
[No Abstract] [Full Text] [Related]
37. Finding legitimacy for the role of budget impact in drug reimbursement decisions.
Niezen MG; de Bont A; Busschbach JJ; Cohen JP; Stolk EA
Int J Technol Assess Health Care; 2009 Jan; 25(1):49-55. PubMed ID: 19126251
[TBL] [Abstract][Full Text] [Related]
38. Improving efficiencies in pharmaceutical distribution channels using the economic order quantity model.
Sullivan DL; Schommer JC
Clin Ther; 1993; 15(6):1146-53; discussion 1120. PubMed ID: 8111811
[TBL] [Abstract][Full Text] [Related]
39. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression.
Zaric GS
Health Econ; 2008 Nov; 17(11):1277-94. PubMed ID: 18186544
[TBL] [Abstract][Full Text] [Related]
40. Drug expenditure in Ireland 1997-2007.
Barry M; Molloy D; Usher C; Tilson L
Ir Med J; 2008; 101(10):299-302. PubMed ID: 19205138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
